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1. Introduction 
Notwithstanding that life expectancy in patients with systemic lupus erythematosus (SLE) has 
improved progressively in the last few decades, the mortality rates remain three times higher 
as compared with the general population (Uramoto et al, 1998). Reported causes of death vary 
according to the region of the world, yet there is agreement on the bimodal curve of mortality 
rate in these patients, with an initial peak occurring early after diagnosis, strongly related with 
disease activity and infections, and a later escalade associated with cardiovascular disease, 
accrued damage, and infections too (Rubin et al, 1985). It may be due to its complexity that 
infectious disease is often considered a grim topic in SLE, but it is undeniable that infections 
are important contributors of mortality in every stage of the disease. 
The range of infections in lupus patients varies widely, from opportunistic infections -
attributable in some level to immunological dysfunction- to common bacterial and viral 
infections with typical or atypical presentations. Moreover, patients with lupus exhibit 
increased proclivity to hospital acquired infections than hospitalized patients with other 
diagnosis. Some authors have stressed out the association that certain conditions have with 
the risk of infections in patients with lupus.  Some of these include: high disease activity, 
specific immune dysregulation; drug-induced immune deficiency; and organ failure due to 
irreversible damage.  
On the other hand, several clinical manifestations like fever, lymphadenopathy, unexplained 
confusion, pulmonary infiltrates, skin and mucosal injuries, coagulation disorders, and others, 
represent true diagnostic challenges for the clinician who may take them as clues of a lupus 
flare, or may be compelled to commence a trial of antimicrobial treatment because these may 
also be the clinical expression of a life-threatening infection, or perhaps, as it often occurs in the 
field treat both conditions simultaneously. Some evidence suggests that certain infections, 
particularly of viral nature, might participate in disease initiation, disease flare or worsening of 
an active lupus condition. 
In this chapter we will review the current information regarding infections in patients with 
SLE, and recommendations to prevent and treat them. 
2. Immune dysfunction and infection in SLE 
Patients with SLE are known to have defects both in the humoral and the cellular branches 
of the immune system. Some of these defects participate in the inadequacy of immune 
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defense against pathogens. The relationship between altered immune function and 
infections in SLE is exceedingly complex, as infectious agents can interact with the immune 
system in several ways, and the immune system itself works as an intricate, overlapping and 
sometimes redundant network of signals and checkpoints under different levels of control. 
Of course, the defective immune function is not universal and as in other aspects of the 
disease, its expression is not homogenous among lupus patients and hence susceptibility to 
different pathogens is reasonably variable. The potential role of macrophage and 
polymorphonuclear defects, reduced numbers and dysfunction of T-cells and B-cells, defects 
in the production of immunoglobulin and altered function of the reticuloendothelial system 
are all considered to take part in the altered immune response against pathogens that is 
present in a proportion of patients with SLE (Sebastiani  & Galeazzi, 2009; Iliopoulos & 
Tsokos, 1996). 
All this is further complicated by the almost obligated use of immunosuppressant drugs to 
control disease activity. Nevertheless, the young readers will be surprised to know that 60 
years ago, lupus was not treated with steroids or immunossuppresants and despite that, 
infection was still one of the major causes of death in lupus patients. (Klemperer, et al 1941) 
2.1 Defects in the complement system 
The complement system plays a crucial role in host defense against pathogens and the 
increased infection rates observed in SLE patients have been attributed in part to defects of 
the complement system that are in turn, frequent in SLE. Genetic deficiencies of early 
components of the classical pathway are major risk factors for the development of lupus, 
particularly C1q deficiency. Since C1q plays an important role in complement activation 
through the recognition and clearance of apoptotic material, antibodies and structural 
proteins on bacteria and viruses, it is not surprising that a deficient state would increase 
susceptibility to infection. Also the consumption of complement components by immune 
complexes is also considered to limit the amount of complement available to be used against 
invading pathogens. Reduction of other components of the complement system comes with 
various risk degrees of specific infections, i.e. C3: encapsulated bacteria, C5-C9: Neisserial 
infections. (Pickering et al, 2000; Figueroa & Densen, 1991) 
2.2 Mannose-Binding Lectin (MBL) and Infections in SLE 
The lectin pathway of complement activation is also implicated in the pathogenesis of lupus 
and most likely in the increased propensity to infections in this disease, as well. MBL is a 
serum protein that serves as a recognition particle in the lectin pathway of complement 
activation. Additionally, MLB may directly opsonise pathogenic microorganisms and 
activate phagocytes. Several studies have demonstrated that variant alleles of MBL are 
associated with an increased risk for the development of SLE. Furthermore, among patients 
with SLE, those homozygous for MBL allelic variants had an increased risk of serious 
infections in comparison with patients heterozygous of homozygous for the normal allele 
(M.Y. Mok et al, 2007a). Other studies have failed to demonstrate a connection between 
functional MBL activity and the occurrence of infections (Bultink et al, 2006). This 
discrepancy between the genotypic and phenotypic data could be explained by the fact that 
functional activity of MBL is not only determined by mutations on its encoding gene. Also, 
the immune system has redundancies and in most cases, increased susceptibility to infection 
with MBL deficiency arises when other factors are inducing immune dysfunction (i.e. 
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immunosuppressive drugs). In fact, low levels of MBL are associated with poorer outcomes 
in severe infections, even in otherwise immunocompetent individuals. In synthesis, a 
proportion of patients with lupus appear to have increased frequency of infections related to 
allele variants of MBL; such infections are for the most part from encapsulated bacteria, and 
most likely owing to defective opsonization (Monticielo et al, 2008; Super et al. 1989). 
2.3 Cellular immune defects 
The diminished phagocytic activity observed in monocytes from patients with lupus, may 
be due to a decrease in the production of TNF-α, deficit in the generation of superoxide, or 
by the presence of specific autoantibodies against receptor Fcγ. These autoantibodies may 
have a wider effect over the immune system because these receptors also exist on the surface 
of B-cells, natural killer cells, and some T-cells (Boros et al, 1993; Yu et al, 1989). Defective 
phagocytosis has also long been noticed in polymorphonuclear leukocytes in patients with 
lupus. Although the presence of antibodies against neutrophil cytoplasmic components, 
some of which are directly involved in pathogen fighting (i.e. lactoferrin, elastase and 
lysozyme), has been reported in SLE, its clinical significance is still obscure. Their presence 
has no influence over total number of neutrophils and their precise contribution to the 
increased susceptibility to infections in SLE, remains to be determined (Lee et al, 1992; 
Schnabel et al, 1995).  
T-cell lymphopenia is the most common quantitative disorder observed in the blood of 
patients with lupus. Lymphopenia correlates with disease flares and responds to 
immunosuppressive treatment. It is generally considered to be a major contributor in the 
increased propensity to infections. T-cells also exhibit important functional deficits. 
Impaired T-cell cytolytic activity is largely attributable to a decreased production of 
interleukin-2 and γ-interferon and is more prominent within the CD8+ T-cell population. On 
top of the reduced delayed hypersensitivity skin response that happens in patients with 
SLE. A group of studies pointed out that an important proportion of patients with SLE have 
altered in vitro immune responses to alloantigens and recall antigens, and that such 
dysfunction correlates with higher disease activity. (Yu et al, 1989; Gumma et al, 1994). 
In general, B-cell functions seem unaltered in SLE. Antibody production and immunization 
are preserved in the majority of cases, but some B-cell and immunoglobulin alterations have 
been described. Scattered reports of transient or permanent hypogammaglobulinemia with 
an increased risk of infections were informed prior to the use of anti-CD20 therapies. 
Alternatively, many patients with SLE display a prominent polyclonal B-cell activation and 
hypergammaglobulinemia (Yong et al, 2008, Karim 2006; Battafarano et al 1998). 
Transient or permanent spleen dysfunction is associated with diverse autoimmune diseases 
including SLE. In SLE, functional asplenia, defined as failure of splenic uptake of a 
radiolabeled colloid is present in approximately 5% and seems to correlate with disease 
activity. Asplenia increases vulnerability to pneumoccocal and Salmonella infections (Fishman 
& Isenbert, 1997). Table 1 summarizes factors predisposing SLE patients to infections. 
3. Epidemiology of infections in systemic lupus erythematosus 
Although infections in SLE remain as an important clinical concern that should have a 
prominent place in the research agenda in lupus, there is a notorious absence of high-quality 
studies addressing this phenomenon. The majority of studies involve hospitalized patients, 
a population that certainly has a selection bias and limits their external validity; also, we  
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Cellular immunity 
  T-cell lymphopenia 
  Impaired T-cell cytotoxic activity 
  Altered recall of antigens 
  Diminution of NK-cell function and number 
 
Humoral immunity 
  Antibodies against Fcγ	receptor	
  Antibodies against neutrophil cytoplasmic components 
  Hypogammaglobulinemia 
 
Phagocytic deficiency 
  Mononuclear cell defective phagocytosis 
  Deficit in superoxide generation 
 
Cytokine defects and other immune anomalies 
  Mannose-binding lectin allelic variants 
  Hypocomplementemia 
  Decrease in the production of TNF-α 
  Decrease of IL-2 production 
  Other cytokine imbalance (IL-10, γ‐interferon,	IL‐1) 
 
Disease related 
  Disease activity and/or glucocorticoid use 
  Transient or permanent spleen dysfunction 
  Accrued damage (irreversible damage, i.e. ESRD, lung fibrosis, etc.) 
 
Treatment related 
  Immunosuppressive drugs 
  Glucocorticoids 
  Immune targeted biologic agents 
 
Table 1. Summary of factors related to infection propensity in SLE 
found a great number of patient series and case reports of outstanding features but only a 
few prospective cohorts in most of which the outpatient setting had been neglected. 
Morbidity of lupus patients varies with the chronological stage of the disease. In subjects with 
short disease duration, the most important causes of hospitalization and medical attention are 
related to disease activity and common bacterial or viral infections and few opportunistic 
infections. With the improved survival rates and longer disease duration, other morbid 
conditions are commonly identified in longstanding disease; the most regularly described are 
accelerated atherosclerosis and cardiovascular disease, osteoporosis, osteonecrosis, cognitive 
dysfunction, chronic fatigue, fibromyalgia, malignancies and the coexistence with other 
chronic illnesses such as diabetes mellitus and systemic hypertension. However, infectious 
disease is still one of the most important causes of hospitalizations and death in this group.  
In a large cohort of patients with SLE followed in several European countries, the annual 
incidence of infection was 27% during the first 5 years. A follow-up report indicates that 
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infections continued to be the cause of one fifth of all hospitalizations in the second half of 
the 10 year follow-up, with a notorious reduction in the diagnosis of sepsis in this later 
period (Cervera et al, 2003). Other authors have reported on the burden of infectious disease 
in SLE: close to 15% of patients with lupus are hospitalized for major infections every year; 
the risk of major infection is 60% higher in SLE as compared with other chronic diseases, 
and many of them are treated in the ICU. A bacterial etiology is detected in the majority of 
cases and lower respiratory tract is the most important site of infection. Mexican researchers 
performed a study to determine the incidence of infections in their group; among the 
ambulatory patients, 57% of hospitalizations were due to infection of any kind, and 
although diagnostic confirmation was achieved only in one third of their cohort, all patients 
with suspicion of infection, received complete antibiotic courses. They found 12.5% of 
nosocomial infections in non-infected subjects admitted for other reasons (Navarro-Zarza et 
al, 2010). Furthermore, Al-Arfaj in Arabia found, in patients followed by almost 30 years 
with a remarkable long-term survival, that 50% of deceases were related to severe bacterial 
sepsis, mainly in subjects with renal failure (Al-Arfaj & Khalil, 2009). Other groups in 
different regions of the world report similar rates of infections in SLE, emphasizing that 
these complications remain as a significant problem both in the outpatient care and in the 
hospital setting.  
Infections are also a prominent cause of death among lupus patients. On the early 1980’s, a 
multicenter evaluation in more than 1,000 lupus patients was reported, revealing that one 
third of registered deaths were caused by infections and another third because of disease 
activity. Other authors, in different regions of the world, have assessed the issue of mortality 
due to infections, and with different methodological approaches, mortality rate associated to 
this cause is reported from 14 to 50% of all deaths (Cervera et al, 2003; Zandman-Goddard & 
Shoenfeld, 2003; Gladman et al, 2002).Table 2 depicts impact of infections in general 
mortality of SLE patients. 
The nature of most infections in lupus patients either in the ambulatory or nosocomial 
settings is mainly of bacterial origin, being lower respiratory and urinary tract infections the 
most frequently registered, with less cases of sepsis of unknown cause, soft tissue & skin 
and other common bacterial infections (Gladman et al, 2002; Iliopoulos & Tsokos, 1996). 
Nevertheless, it should be underlined that non-complicated infections occurring on 
ambulatory settings are not usually recorded, and it is possible these may be 
underestimations of the true burden they give. In a prospective study of an outpatient clinic, 
an incidence of 32% of infections along 2 years of follow-up was observed. Urinary tract 
infections (UTI) due to Escherichia coli, skin infections produced by Staphylococcus aureus, and 
simultaneous infections of different sites were the most frequently registered; the majority 
were treated on ambulatory basis with good results (Zonana-Nacach et al, 2001).  
Nosocomial infections are a noteworthy issue to address in this scenery. Some investigators 
reported that more than a half of infections diagnosed in SLE patients are of a nosocomial 
source, mostly upper and lower respiratory and bloodstream infections; patients with organ 
dysfunctions and with high-steroid dose are more susceptible to acquire nosocomial 
infections. The most important information in this regard comes from Navarro-Zarza’s 
cohort, indicating an incidence rate of 12.5% among patients who had neither symptoms nor 
clinical suspicion of infection at admission, and afterward develop nosocomial infections; 
higher disease activity score measured by the Mex-SLEDAI (Guzmán et al, 1992), high 
damage scores (SLICC/ACR), immunosuppressive treatment and length of hospital stay 
were all risk factors for the development of nosocomial infection (Navarro-Zarza et al, 2010). 
www.intechopen.com
 
Systemic Lupus Erythematosus 
 
412 
Consequently, lupus patients admitted for hospital care are at higher risk of infection and 
any action to lower their incidence, by every member of the healthcare team should be 
implemented with emphasis. 
 
Author, year/Site 
# of patients 
followed by time 
# of 
deaths 
Survival 
% of deceases 
due to 
infections 
C.C.Mok, 2000/China 186 by 7 y 9 93% - 5 y 75% 
Kasitanon, 2002 
/Thailand 
349 by 14 y 52 84% - 5 y; 75% - 10 y 35% 
Cervera, 2003/Europe 1,000 by 10 y 68 97% - 5 y; 92% - 10 y 25% 
Pons-Estel 2004/Latin 
America 
1,214 by 3 y 34 ND 58% 
Bernatsky, 2006/North-
America§ 
9,547 by 30 y 1,255 ND 5% 
Wadee, 2007/South 
Africa 
226 by 15 y 55 72% - 5 y; 58% - 10 y 44% 
Nossent, 2007/Europe 2,500 by 5 y 91 ND 57% 
Al-Arfaj, 2009/ Saudi 
Arabia 
624 by 30 y 25 98% - 5 y; 97% - 10 y 48% 
Goldblatt, 2009/UK 104 (of 407) by 29 y¶ 67 ND 25% 
¶ Only reports results of 104 patients hospitalized form a cohort of 470 
§ Study in 23 Centers of US, Canada and UK, only 1 in Sweden and 1 in Iceland 
Table 2. Percentage of deaths due to infections in some studies around the world. 
Infectious diseases in SLE patients admitted to the ICU require an additional comment. 
Most admissions to the ICU in lupus patients are related to infection, and a considerable 
mortality is usually observed (45-86%); the most often reported predictive markers are: 
higher APACHE-II scores, length of stay in the ICU, and inadequate initial selection of 
antibiotics. It has been shown that not infected patients with SLE admitted to the ICU with 
lupus flares, exhibit high mortality rates (75-95%), and nosocomial acquired infections are a 
relevant complication in most cases. These reports, as well as others (Alzeer et al, 2004), 
highlight the importance of pneumonia and bacterial sepsis of unknown origin as the most 
frequent reason for admission to ICU, and their relationship with poor outcomes. 
3.1 Usual bacterial infections 
Common microorganisms underlie the majority of infections among lupus patients. 
Pneumonia and respiratory tract infections are the most recognized (Petri, 2008). Some 
immune defects increase susceptibility to certain bacteria, but no comparative studies have 
made clear the possible connection that such defects may have with specific infections. 
Continuing on the subject of common infections, S. aureus and Streptococcus pyogenes persist 
as the most frequent etiology of respiratory infections. However, as mentioned, information 
related to respiratory infection in the outpatient setting is scarce, and not surprisingly 
pathogens differ in the hospitalized subject; gram-negative bacteria appear as key pathogens 
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in respiratory infections in these circumstances, being Klebsiella sp, Pseudomonas aeruginosa, 
and E. coli mainly involved. Streptococcus pneumoniae has been reported as a cause of 
septicemia; interestingly, lower rates of pneumococcal septicemia have been seen after the 
implementation of routine vaccination. 
Bladder dysfunction seems to be more prevalent among women with SLE; in an outpatient 
cohort, near to 10% suffered of recurrent infection and depict abnormal voiding function 
tests, with small bladder capacity, reduced bladder sensation, residual urine and abnormal 
urinary flows. These data were alike to those reported by others, and also shows a possible 
association of these abnormalities and disease activity. Urinary tract infections are very 
common among women with SLE, and the functional derangements previously mentioned 
are found often, particularly in cases of recurrent infections. E coli and Streptococcus agalactiae 
were the most prevalent recovered microorganisms (Durán-Barragán et al, 2008). 
Infections due to Salmonella species are important cause of bacteremia after ingestion of 
contaminated food; inasmuch as underdeveloped countries have more risk conditions to 
this infection, it has been reported more frequently in these regions of the world. Lupus 
patients’ conditions are prone to develop primary bacteremia, extra-intestinal collections, 
osteomyelitis, septic arthritis, infective endocarditis, bloodstream and endovascular 
infections, even in absence of gastrointestinal symptoms. Infections of different Salmonella 
serogroups are also related to high mortality, as it has been shown after bacteremia 
episodes. Risk factors for mortality due to Salmonella infection are re-infection, older age and 
concomitant infection with other microorganisms; a high index of suspicion is vital, insofar 
as salmonellosis and SLE have similarities in clinical manifestations like fever, rash, 
pleurisy, abdominal complaints and synovitis. Table 3 describes the main pathogens 
observed in prospective or relevant studies in different regions of the world. 
3.2 Infections due to Mycobacteria 
Infections as a consequence of Mycobacterium species are of two groups: infections due to M 
tuberculosis, that trend to occur early in the course of lupus, related to disease activity and 
treatment, and usually resulting mainly from reactivation of latent infection or to 
reinfection; and infections to non-tuberculous Mycobacterium (NTM), presenting later in the 
course of disease and predominantly as a new infection, including M. avium complex, M. 
chelonae, M. haemophilum or M. fortitum (Cuchacovich & Gedalia, 2009). Mok et al (M.Y. Mok 
et al, 2007b) describes 11 cases of NTM infections localized in skin and soft tissues, in 
patients with long disease duration and long cumulative prednisone dose. In transplant 
patients, SLE remains as a risk factor for tuberculosis with a substantial increase of mortality 
among patients with this infection. 
Mycobacterium tuberculosis infections represent a great problem to many countries around 
the world. The HIV pandemic and use of biologic immune-regulator agents for other 
rheumatic conditions are related to rise of tuberculosis (TB) in regions where TB was 
believed near to ending (Mathers & Loncar, 2006). In point of fact, since the first use of high-
steroid doses in rheumatic diseases, an increase of TB infections was noticed, as well as 
reactivation of previously treated TB once steroids were newly administered (Yun et al, 
2002); besides, occurrence of TB is closely and directly interrelated to the mean daily doses 
or cumulative steroid-dose. In lupus patients, TB is a major contributor of morbidity and 
mortality. There seems to be a higher risk for this infection and clinical illness in these 
patients is often extra-pulmonary (miliary) where hematogenous dissemination is usually  
www.intechopen.com
 
Systemic Lupus Erythematosus 
 
414 
Author, year/Site 
# patients 
observed 
# of 
infections 
Main pathogens 
(Percentage of total) 
Characteristics 
Oh, 
1993/Singapore 
28 38 
S. aureus (21%) 
P. aeruginosa (11%) 
Klebsiella sp. (11%) 
E. coli (7%) 
M. tuberculosis (7%) 
 
Hospitalized patients 
followed by 8 months 
Zonana-Nacach, 
2001/Mexico 
200 65 
E. coli (25%) 
S. aureus (8%) 
Candida sp. (6%) 
M. tuberculosis (2%) 
Salmonella sp. (2%) 
 
Outpatient only. Two 
years of observation 
Leone, 2007/Brazil 71 48 
S aureus (50%) 
P. aeruginosa (17%) 
Candida sp. (17%) 
Aspergillus sp. (17%) 
 
Juvenile SLE, 18 
deaths.  
Ramírez-Gómez, 
2007/Colombia 
ND 123 
E. coli (22%) 
Staphylococcus sp. (15%) 
Klebsiella sp. (9%) 
Candida sp. (9%) 
P. aeruginosa (4%) 
 
All nosocomial 
acquired. High 
disease activity 
(SLEDAI > 11). Three 
years of observations 
Ruiz-Irastorza, 
2009/Spain 
249 88 
E. coli 16% 
S. aureus 14% 
M. tuberculosis 12% 
S. pneumoniae 9% 
Candida sp. 7% 
 
Major infections 
(organ dysfunction, 
hospitalized) 
Navarro-Zarza, 
2010/Mexico 
473 
268  
(confirmed 96) 
E. coli (48%) 
Candida sp. (21%) 
Staphylococcus sp. (15%) 
Streptococcus sp. (12%) 
M. tuberculosis 4.5% 
 
Community acquired 
infections seen along 
5 years 
Table 3. Pathogens frequency in some prospective studies around the world 
the mechanism involved (Hou et al, 2008). Extra-pulmonary tuberculosis presents a wide 
range of symptoms, which may confound with other diseases, or with disease activity; 
symptoms like arthritis, lymphadenopathy, lung nodules, pulmonary infiltrates, pleural 
effusion, weight loss and renal abnormalities offer this challenge, so, workup to identify 
mycobacteria is imperative. Moreover, in a review of patients with central nervous system 
involvement, M. tuberculosis represents a frequent cause of meningitis that requires prompt 
recognition and treatment, since it is linked to high mortality and severe functional sequels 
(Yang et al, 2007). Burden of TB in SLE is higher in countries were TB is endemic; for 
instance, incidence may vary from less than 1% in industrialized countries to 11.6% in India 
(Falagas et al, 2007) with a 6-fold risk of TB among SLE patients in Spain to 15-fold in Hong 
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Kong and 60-fold in India. In a study of overall infections among lupus patients, TB was the 
most frequently diagnosed and extra-pulmonary localization was present in one quarter of 
patients. In addition, TB was found during the first year of lupus diagnosis in 60% and 80% 
in the first 24 months, mainly linked to a major organ dysfunction or aggressive treatment 
(Shyam & Malaviya, 1996). 
Diagnosis of TB and NTM infections in lupus patient represents a challenge for clinicians 
due to the overlap of symptoms and laboratorial abnormalities produced by both 
conditions; however, search for mycobacteria in tissues and corporal fluids, cultures and 
serological test, even with genetic material amplification, as well as ADA assay, tuberculin 
test, and γ-interferon assays seem to be equally accurate than in non-SLE patients. It’s fair to 
mention that some variations have been reported in the diagnostic yield of some of these 
tests that require further assessment. (Prabu et al, 2010). Treatment of TB and NTM 
infections should be provided accordingly to WHO guidelines taking into account the local 
antimicrobial resistance rates. The question of isoniazid prophylaxis in these patients will be 
discussed later. 
3.3 Opportunistic infections 
Immunological abnormalities in lupus patients related to dysregulation of both, humoral 
and cellular responses have been extensively documented. Besides, drugs used to treat SLE 
exert diverse degrees of immune system turndown that deepen the problem of immune 
fighting against pathogens (I. Kang et al, 2003). Opportunistic infections, considered as those 
caused by non-pathogenic microorganisms not often seen in individuals with normal 
immune conditions, which lead to clinically significant consequences in 
immunocompromised subjects, are frequently reported in SLE patients. Furthermore, its 
difficult to know the real load that this type of infections represent in SLE since frequency 
rates  are yet to be determined for most of them. On the other hand, case-reports and small 
case series are abundant on this topic. Nonetheless, in all cohorts describing lupus patients 
with infectious diseases there are cases with opportunistic infections either of bacterial, 
fungal, protozoan or viral origin; lot of cases had overlapping manifestations between 
disease activity and infection leading to treatment delay and poor outcomes. 
3.3.1 Opportunistic infections of viral origin 
Viral infections in SLE have been suspected to play a pathogenic role on development, 
trigger and flare of disease. Some authors have demonstrated activation of immune system 
and antibodies production during acute viral infections, as we mentioned before. On the 
other hand, besides its suggested pathogenic role in autoimmune diseases, acute viral 
infections are frequently reported as partners of disease flares or at disease presentation, 
confusing and favoring misinterpretation of clinical signs and deferral of adequate 
treatment (Ramos-Casals et al, 2008). 
Herpes zoster (HZ) is the symptomatic reactivation of the varicella-zoster virus (VZV), an 
infection frequently acquired at childhood; virus prevails in a latent stage in the dorsal root 
ganglia for long periods of time; more than 90% of adults have serologic evidence of a 
previous VZV infection. Control of latent virus at ganglia is exerted by humoral and cellular 
mechanisms; its reactivation requires a change of immune system balance. The incidence 
rate of HZ is 32.5/1,000 patients-year, from a group of prospectively followed lupus 
patients, which is at least 2-3 fold greater than the general population (T.Y. Kang et al, 2005). 
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In a national survey in an Asian country, SLE was the most important risk factor to develop 
HZ at population level. Major complications of HZ are visceral dissemination with CNS, 
lung and liver involvement. Use of immunosuppressant drugs is the most relevant risk 
factor for complicated HZ; presence of lupus nephritis and disease activity has been also 
mentioned. Particular genetic abnormalities have not been found in association with HZ 
infection. Lupus patients have more severe forms of infection, with disseminated disease in 
11-20% of cases, higher number of cases with ocular involvement, and post-herpetic 
neuralgia (Borba et al, 2010). Treatment of this condition should be carried out accordingly 
to current guidelines. A live attenuated varicella virus vaccine has not been tested in SLE 
patients and is not recommended in patients using any type of immunosuppressant. 
Cytomegalovirus (CMV) infection is a life-threatening that endangers organ function in 
immunocompromised host, either as primary infection or as a reactivation of latent CMV. 
Although in other conditions associated with immune dysfunction reports of visceral, eye, 
CNS involvement and graft rejection due to this viral disease are ubiquitous. CMV infection 
is also relevant in pregnant women since it is a frequent cause of newborn morbidity and 
mortality. Seroprevalence of CMV antibodies in healthy population have been found to 
range from 50 to 80% in US. In lupus patients, clinical infections often come from 
reactivation of latent virus when aggressive immunosuppressive therapy is installed. 
Clinical pictures are wide: pneumonia and alveolar hemorrhage, skin ulcers, proteinuria 
and renal failure, thrombocytopenia, pancytopenia, hepatitis, vasculitis, retinitis and 
encephalitis. It may be underseeked and hence underdiagnosed but only few cases with any 
of these complications are reported in SLE (Ramos-Casals et al, 2008). Diagnosis of CMV is 
made with serology, although a note of caution should be taken: false positive reactions are 
not infrequent, presumably because of secondary production by auto-reactive B-cells. Other 
tools for diagnosis are DNA amplification of viral material as well as the characteristic 
cellular changes seen in biopsies. Antiviral agents to treat this disease should be initiated 
once a reasonable suspicion is present because it is linked to a considerable mortality and 
irreversible organ dysfunction, and in the clinical arena it is often difficult to wait for an 
unquestionable diagnosis; ganciclovir and its pro-drug valganciclovir, foscarnet and 
cidofovir are currently used in this setting, with the necessity of a tight monitoring due to its 
potential serious adverse effects. Up till now, attempts to develop an effective vaccine to 
prevent CMV infection by several researches around the world, either in the general 
population or in some special groups, have not been successfully (Gandhi & Khanna, 2004). 
Epstein-Barr virus (EBV) infection importance resides in its temporal relationship with lupus 
initiation; moreover, EBV infection is relevant because of the immunological abnormalities 
found during and after exposure to this virus (Barzilai et al, 2007), the defective control of 
latent infection seen in lupus patients (I. Kang, 2004) and the higher prevalence of serum 
antibodies against EBV observed in subjects with SLE as compared with other patient groups. 
In Ramos-Casals’ review, only a few cases with EBV infection were obtained, and no patient 
had organ-specific involvement; such cases had lymphadenopathy, fever and rash often 
considered manifestation of disease activity may well represent mild infections with EBV. We 
found very interesting a report of lymphoma with EBV infection in a patient receiving 
azathioprine that regressed after withdrawal of immunosuppressive therapy (Evans et al, 
2008). No specific treatment for this condition has been described. 
Human papillomavirus infection has demonstrated to be cause of genital, rectal and 
laryngeal cancer. Uterine cancer is the most important malignancy of those linked to HPV 
infection, due to its high incidence in third world countries. In 2010 it remains a public 
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health problem in poor countries, in spite of the many healthcare programs of prevention, 
early detection and treatment of pre-malignant lesions (Clifford et al, 2005). Lupus women 
have higher prevalence of HPV infection compared with a control group, as well as high-
risk variants of the virus (Klumb et al, 2010). Furthermore, there might be more risk  
of squamous intraepithelial lesion because of a higher prevalence of identified factors of 
disease progression, such as persistence of high-risk HPV variants and the use of 
cyclophosphamide.  Progression to neoplasia is probably more frequent among SLE patients 
also. Therefore, SLE women require close follow-ups, particularly in women with sexual 
activity and/or presence of the virus in the cervix. Treatment of those with high-risk 
variants and adherence to management guidelines of squamous epithelial lesions  
and cervical intraepithelial neoplasia should be warranted. No evidence of impact of 
recently applied programs of vaccination in these patients can be made due to current short 
length of follow-up. 
Parvovirus infection has also been associated with pure red-cell aplasia, hydrops fetalis and 
acute and chronic arthropathy; other clinical manifestations such as rash, fever, 
lymphadenopathy, and blood cell abnormalities may also puzzle the clinician into a 
misdiagnosis of SLE. Careful assessment and follow-up will differentiate between both 
conditions (Severin et al, 2003). Diagnosis of infection is made by serology or viral DNA 
amplification, no treatment for this condition has been described as a great majority of cases 
have self-limited disease. No methods of prevention are available. 
Hepatitis C-virus (HCV) infection has a worldwide distribution and is endemic in some 
regions. It is the most common cause of chronic liver disease and the global prevalence has 
been estimated in 2%, more than 120 million people around the world might be currently 
infected (Shepard et al, 2005). Coexistence of SLE and HCV infection is therefore not an 
unusual treat. HCV infection is the viral illness with the most described muscle skeletal and 
autoimmune manifestations resembling rheumatic conditions, mostly acute and chronic 
polyarthritis, vasculitis, glomerulonephritis, neuropathy, thrombocytopenia, cryoglobulinemia 
and other laboratory anomalies, including positive antinuclear antibodies, low complement 
levels and anti-DNA antibodies, which are indistinguishable of the idiopathic diseases. In a 
comparison of lupus patients with and without HCV infection, some authors found a large 
prevalence of infection among SLE patients belonging from the same population, with lower 
frequency of cutaneous features and anti-dsDNA antibodies, as well as a higher prevalence of 
cryoglobulinemia, hypocomplementemia and liver test abnormalities (Ramos-Casals et al, 
2000). HCV infection may mimic not only SLE, but Sjögren syndrome, polyarteritis nodosa 
and rheumatoid arthritis also (Sharlala & Adebajo, 2008; Becker & Winthrop, 2010) and may 
play a pathogenic role in autoimmune thyroiditis and Behçet´s disease. On the other hand, α2-
interferon therapy used for the treatment of chronic HCV may induce SLE which may or may 
not regress after withdrawal. Also, clinicians should bear in mind that SLE has been described 
as a remarkable cause of false positive serology for HCV. 
Other viral infections in lupus patients such as mumps, measles, herpesvirus-6, or herpes 
simplex virus are seldom reported and seem not to have relevance interactions of these viral 
agents and SLE (Ramos-Casals et al, 2008).  
3.4 Rare bacterial infections 
Listeria monocytogenes is a ubiquitous pathogen that causes disease in animals and humans. 
Outbreaks of listeriosis in relation to contaminated food have been reported in 
immunocompetent hosts. In immune deficient patients it is frequently a fatal infection with 
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sepsis and CNS involvement. In an analysis of 38 lupus patients with CNS infections, Yang 
et al (Yang et al, 2007) found tuberculosis in a half, L. monocytogenes in 3, other gram-positive 
and gram-negative bacteria in 3 cases, Cryptococcus neoformans in 12 and Aspergillus 
fumigatus in 1; high steroid dose and low albumin were related to unfavorable outcome.  In 
other series, listeriosis mainly manifested as meningitis in SLE patients with remarkable 
high mortality (Kraus et al, 1994). Antibiotic regimen in acute bacterial meningitis in lupus 
patients should include an agent with anti-listerial activity.  
The Nocardia genus includes a group of soil gram-positive saprophyte aerobic actinobacteria. 
Nocardia causes human infections that are difficult to diagnose because of unspecific clinical 
or histological manifestations. There are reports of several lupus cases complicated with 
Nocardia infections; lungs were the most common site of involvement (81%), followed by the 
central nervous system (C.C. Mok et al, 1997). A high degree of suspicion to identify this 
infection is required.  
3.5 Opportunistic Infections of fungal origin 
Fungal infectious disease is more often recognized in hospitalized patients owing to the 
more extensive use of broad-spectrum antibiotics. In lupus patients, the most common 
fungal infections are, as in other chronic immune deficient states, those produced by Candida 
species, which may affect pharynx, esophagus, and the urinary tract or may present 
themselves as a primary bloodstream infection. A relationship with high steroid doses and 
intense immunosuppression is suggested by many. Pneumocystis jiroveci (formerly carinii) 
has been acknowledged as a cause of severe pulmonary involvement in chronic disease with 
deficient immune function. There are several reports of P. jiroveci pneumonia in patients 
with rheumatic disorders after intense immunosuppression. It has been suggested that SLE 
patients have more dramatic disease behavior and higher mortality rates, but this remains 
speculative. Patients receiving high dose steroids (>40 mg of prednisone or equivalent, for 
more than three months) or a combination of immunosuppressants, and with lung 
involvement of SLE (i.e. autoimmune alveolitis) may be considered for a prophylactic trial 
of antimicrobials. (Vernovsky & Dellaripa, 2000). 
C. neoformans is ubiquitous encapsulated yeast that causes severe neurological infections and 
other disseminated diseases in immunocompromised hosts. In several fatal cases of lupus 
patients with meningeal infection, C. neoformans has been seen as a causative agent. 
Moreover, in a group of lupus patients with invasive fungal infections, C. neoformans 
represented almost 70% of cases, with both meningeal and disseminated disease. Prompt 
initiation of active antifungal treatment is mandatory in accordance to the elevated mortality 
registered in these cases. Other fungal agents such as Aspergillus fumigatus and mucor 
species have been reported and recently reviewed (Arce-Salinas et al, 2010). 
3.6 Parasitic infections in SLE 
Parasitic diseases remain as a major cause of morbidity and mortality in the tropical areas 
and in the underdeveloped world. Malaria persists in at least 109 countries and affects 300 
million people around the world. No relevant association with clinical manifestations of 
lupus or with its treatment has been reported. Also, no particular clinical picture of 
malaria in this population has been mentioned. Nevertheless, relationship of the parasite 
and lupus resides in the production of antibodies cross-reacting against Plasmodium 
parasites found in some patients (Zanini et al, 2009); and the fact that anti-ribosomal P 
protein antibodies produced by lupus patients cross-react with the ribosomal 
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phosphoprotein P0 of Plasmodium falciparum and exert a potent inhibition of the parasite 
growth in vitro (Singh et al, 2001), the clinical significance of this interesting observation 
remains elusive. On the other hand, IgM anti-phospholipid antibodies have been 
recognized in patients with active malaria infection (Jakobsen et al, 1993), mainly against 
phosphatidylinositol, phsophatidylcholine and cardiolipin; high titers correlated with 
infection severity and poor outcome.  
Exposure to Toxoplasma gondii accordingly to seroprevalence studies is widely distributed; 
its importance increases in pregnant women (increased risk of fetal neurological damage), 
and in immune deficient hosts, in whom encephalitis, retinal damage, pneumonitis and 
other severe manifestations may occur. In lupus patients there are a few case-reports of 
patient with neurological or ocular involvement, as well lymphadenopathy and fever, again 
mimicking disease activity (Seta et al, 2002).  
Strongyloides stercoralis, a soil worm that infects humans in tropical areas should be in mind 
of every clinician caring for SLE patients. S. stercolaris clinical infection has a prevalence that 
ranges from 0.1 to 11% depending the way in which it is sought (serum antibodies, stool ova 
or other methods). Generally its infection produces a few intestinal symptoms and its 
relevance, besides its infectivity, is a consequence of the autoinfection cycle that permits 
blood larvae migration. Without effective cellular immune control disseminated disease 
develops. Some lupus cases complicated with overwhelming strongyloidosis have been 
described; some authors suggest that stool examination looking for parasite’s ova and 
preventive treatment could be recommended for patients at risk who will receive intense 
treatment for SLE. Albendazol or ivermectin have been used in chronic and disseminated 
infection, and the few reports describing this condition are related with poor outcome 
(Caramaschi et al, 2010).  
4. Approach to fever in SLE 
Fever in lupus patients represents a challenge for the clinician, who must face up with 
finding ways to determine the most likely origin between a lupus flare and active infection, 
bearing in mind that often both require prompt treatment. In an old report Harvey, said 
fever was a manifestation of disease activity in at least 86% of their patients, later Daniel 
Wallace draw attention to the decline of fever as a symptom of disease activity in reports of 
the 1980’s and early 1990’s; he thought that such decrease was related with frequent and 
earlier use of NSAIDs and glucocorticoids. Moreover, febrile lupus patients are habitually 
seen in both the outpatient clinic and the hospital wards. The workup requires an intelligent 
and sequential approach to recognize the true nature of fever. Lupus patients with fever 
may show certain patterns of clinical behavior that correspond, more or less, to clinical 
scenarios that entail different actions. Firstly, a patient recently diagnosed, without 
treatment and with active lupus disease including fever among other manifestations; in 
these cases, treatment beginning, particularly with steroids, produces a rapid disappearance 
of fever; when fever persists, the search of an infectious source is mandatory with 
appropriate cultures. Secondly, patients with fever who have inactive disease or mild 
disease activity in their last follow-up visits, often in the outpatient situation, and may or 
may not be receiving low steroid dose, antimalarials or a mild immunosuppressive regimen; 
in this cases, a thorough clinical assessment and studies in hunt of common bacterial 
infections followed by currently recommended empirical antibiotic treatment is warranted 
and associated with resolution of fever. 
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In a lupus patient hospitalized because of persistent fever, a meticulous clinical evaluation is 
critical, followed by the workup study based on its findings and suspected diagnosis; an 
assessment of disease activity with a validated index is also suggested, activity biomarkers 
are not perfect discriminative elements and are not always available. Adjustment of lupus 
treatment or initiation of a trial of empiric antibiotics should be determined based on the 
initial findings and patient status. Often both are required initially and tailored when a 
clearer scenario is at hand. An extensive assessment of a lupus cohort tested two 
hypotheses, demonstrating that fever is rarely associated with lupus flares in patients taking 
low dose of prednisone (median 10 mg per day), with only one case presenting with fever 
among 73 flare episodes (Rovin et al, 2005). And also, in SLE patients with recent onset 
fever, moderate doses of prednisone (20 to 40 mg/day) were related with a rapid resolution 
of the symptom, except in cases when infection was the cause. 
Differentiation between infection and disease activity is highly important but difficult. 
Acute infections, systemic response to infection and disease activity share many clinical and 
laboratorial abnormalities. Certain biomarkers have been proposed as discriminative 
elements in such scenarios. C-reactive protein could be a useful tool to differentiate both 
conditions (Roy & Tan, 2001), although others reports do not support this, it is our believe 
that the issue remains inconclusive. Procalcitonin, a precursor of calcitonin hormone is a 
novel marker of bacterial infection; nowadays, determination of serum level is routinely 
performed in hospitals as a bedside rapid measurement to provide evidence of bacterial 
infection, in circumstances when clinical or bacteriological diagnosis is not clear. It was 
suggested, that procalcitonin might be useful for distinction of infection or disease activity; 
however, a recent careful evaluation rejected this hypothesis; procalcitonin exerted a poor 
diagnostic accuracy for differentiation of both conditions, and is no longer being used with 
this purpose (Lanoix et al, 2011).  
Systemic lupus is also reported as a cause of fever of unknown origin (FUO) in different 
settings, corresponding to a relevant proportion of cases with this entity being in some 
reports a repeated diagnosis among the inflammatory non-infectious conditions, which 
represent at least one third of all causes of FUO (Arce-Salinas et al, 2005). 
5. Prevention strategies 
Preventive strategies should begin with the identification and amendment of factors that 
predispose SLE patients to infections. This is, however easier said than done. Even though 
infection rates were as high as 40% prior to the widespread use of corticosteroids for the 
treatment of SLE, several studies have demonstrated that high dose steroids, the current 
angular stone of SLE treatment, increase the risk of infection. Weaker associations have been 
reported with the use of cyclophosphamide. Other commonly reported risk factors for 
infection in SLE are: high disease activity, damage accrual, nephritis and neurologic disease 
activity (Gladman et al, 2002; Fessler 2002). No published evidence has shown that the 
steroids effect over the risk of infection is independent of disease activity, and this will 
probably remain as it is, in view of the difficulty to dissect these two conditions. 
Considering this information it seems fair to admit that measures aimed at lowering disease 
activity should be considered the backbone of the preventive strategy against infection in 
SLE, even given their immunosuppressive nature. 
Although inconclusive evidence suggests that certain measures of prophylaxis against 
infective pathogens may be in order for specific subgroups of patients based on their 
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particular risks (Table 4), there are no guidelines as to which subgroups of patients may 
benefit the most, the agents that should be used, and the best timing to do so. 
 
Respiratory 
Infections 
 Influenza vaccination safe and effective (antibody response) in 
SLE. (Abu-Shakra et al, 2007) 
 Pneumococcal vaccine safe. Significant minority left unprotected 
(risk factors: high disease activity and immunosuppressive use). 
(Battafarano et al, 1998) 
Tuberculosis 
 Screening for latent TB is critical prior to high dose PDN and other 
lupus drugs (anergy is frequent). (ATS, 2005) 
 In endemic areas prophylaxis with isoniazid may reduce the risk 
of developing TB in patients taking > 15 mg/day of PDN 
(Hernández-Cruz B et al, 1999). 
Herpes Zoster 
 Frequency of herpes zoster is higher in patiens taking CFM than 
other lupus drugs. Lower doses of CFM reduce risk (Houssiau F 
et al, 2002). 
 No data on (live attenuated) vaccine use in patients with SLE. 
B & C Hepatitis 
 Minimal data on the course of HBV and HCV infections, antiviral 
treatment in SLE, and effect of lupus drugs in viral replication and 
hepatic necrosis. 
 Increase risk of autoimmune symptoms after HBV vaccine (Geier 
D.A. & Geier M.R., 2005). 
 Effect of SLE on response to HBV vaccination not clear. 
Fungal 
infections 
 No primary prevention is suggested for Candida, Cryptotoccus or 
Aspergillus. 
 Prophylaxis for pneumocystis in severe lupus mostly with lung 
involvement is suggested (Vernovsky & Dellaripa, 2000). No real 
data.  
Other 
 Meningococcal vaccination recommended in asplenia but not 
formally examined in SLE 
 Haemophilus influenzae type B recommended in asplenia. Safe and 
effective in SLE (antibody response). (Battafarano et al, 1998) 
Table 4. Preventive Management of Selected Infection in SLE. 
A common problem that physicians often face is whether immunization is a safe and 
effective strategy to prevent infections in patients with SLE or not. Concern has been raised 
from a group of reports that link vaccination to autoimmune manifestations. However, data 
from observational cohorts denotes that vaccinations are safe for the majority of SLE 
patients, when inactivated and component vaccines are used. For instance, a group of 70 
patients with SLE received pneumococcal, tetanus and H. influezae type B vaccines, and none 
had a disease flare or any significant change in the activity status. (Battarfarano et al, 1998). 
The efficacy of vaccination in SLE remains elusive for the majority of vaccines. While most 
patients with SLE show an antibody response to vaccination, this does not imply that the 
patients actually gain an advantage against the pathogen. No study so far, has looked into 
the true protective effect (i.e.: rates of pneumonia infection) that vaccines are supposed to 
offer, in patients with SLE. 
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The reader is encouraged to read the guidelines proposed by the British Society for 
Rheumatology (www.rheumatology.org.uk). Here it is recommended that live vaccines 
should not be used in patients taking immunosuppressive drugs or a few months after 
cessation of them. They also recommend that when non-live vaccines are given, an 
assessment of response should be sought, and to consider a booster when antibody titers are 
low. Finally, Barber et al proposed a set of strategies for prevention of opportunistic 
infections in SLE, briefly: yearly influenza vaccination, quinquenal pneumococcal 
vaccination, regular pap smears, TB skin test prior to starting immunosuppressive treatment 
and treatment with isoniazid for patients with latent TB infection. Hepatitis B, hepatitis C 
and HIV serology should be screened at baseline, as well as S. stercoralis in endemic areas 
(Barber et al, 2011). 
6. Final remarks 
It has been said that infections loom, like the Sword of Democles, over patients with SLE, 
and this is certainly not an understatement. About half of the patients with SLE will suffer a 
major infection in their lives and a great proportion of them will have an infection 
attributable death. In spite of this, only a few studies have addressed the issues that would 
provide clinicians with better management alternatives for infectious disease in SLE and its 
prevention. It is believed that SLE patients are at high risk for infections owing to intrinsic 
underlying immunological derangements and to the use of therapeutic regimens with 
immunosuppressive agents. 
The use of high dose glucocorticoids, high disease activity, organ dysfunction and use other 
immunosuppressants, are the strongest risk factors for the development of an infection in SLE.  
Fever, among other findings challenges the clinician into a discriminative endeavor to 
establish its relation with disease activity and/or infection. Workup in such scenarios 
depends on a thorough physical exam. Some biomarkers have been proposed to be 
discriminative in this situation. 
Specific measures of prophylaxis may offer benefit in patients with lupus against infection, 
but for the most, no controlled studies support their use. Reports of autoimmune induction 
with vaccination are scarce and for the majority of patients, vaccination is a safe procedure. 
Pneumococcal and influenza vaccinations are recommended, but no probe of true efficacy 
exist for these or other vaccines in patients SLE.   
Many questions remain unanswered in the field of infections and SLE, among others: 1) 
Determining true predictors of infection in SLE such as specific immune defects, genetic 
markers or other biomarkers that indicates proclivity to infection. 2) Studying which specific 
immune derangements underlie the increase susceptibility to specific infections. 3) 
Evaluating which measures is likely to prevent infectious disease in SLE patients, who 
should receive them and what is the best timing to do so; these include studies of long-term 
efficacy vaccines and cost-effectiveness of their routine application in SLE. 4) Testing of 
proposed biomarkers that may help clinician solve a frequent diagnostic dilemma between 
disease activity and active infections. 
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